Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA1 | P56199 | 3/20 | 0.47 |
| ▸ | SGK1 | O00141 | 8/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717898 | 0.93 | SGK1 (0.46) | ITGA1SGK1PFKFB3BRD4MAPK10 | |
| SCHEMBL6714964 | 0.92 | SGK1 (0.49) | ITGA1SGK1PFKFB3BRD4MAPK10 | |
| SCHEMBL6716678 | 0.91 | ITGA1 (0.46) | ITGA1SGK1PFKFB3BRD4MAPK10 | |
| SCHEMBL6720563 | 0.90 | PFKFB3 (0.55) | ITGA1SGK1PFKFB3BRD4MAPK10 | |
| SCHEMBL6718780 | 0.87 | SGK1 (0.47) | ITGA1SGK1LMNA | |
| SCHEMBL6718834 | 0.85 | SGK1 (0.47) | SGK1PFKFB3BRD4MAPK10CA1 | |
| SCHEMBL6715037 | 0.84 | SGK1 (0.45) | SGK1PFKFB3BRD4MAPK10LMNA | |
| SCHEMBL6717907 | 0.84 | PFKFB3 (0.55) | ITGA1SGK1PFKFB3BRD4MAPK10 | |
| SCHEMBL6720387 | 0.83 | PFKFB3 (0.52) | ITGA1PFKFB3BRD4MAPK10FABP4 | |
| SCHEMBL6718381 | 0.83 | SGK1 (0.45) | SGK1PFKFB3BRD4MAPK10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | ITGA1 4550/4885SGK1 4293/4885PFKFB3 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.